The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Public ClinicalTrials.gov record NCT02510261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Study identification
- NCT ID
- NCT02510261
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 211 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2015 (Actual)
- Primary completion
- Nov 23, 2022 (Actual)
- Completion
- Nov 23, 2022 (Actual)
- Last update posted
- Dec 6, 2023
2015 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | La Mesa | California | — | — |
| Clinical Trial Site | Aurora | Colorado | — | — |
| Clinical Trial Site | Jacksonville | Florida | 32224 | — |
| Clinical Trial Site | Chicago | Illinois | — | — |
| Clinical Trial Site | Baltimore | Maryland | — | — |
| Clinical Trial Site | Boston | Massachusetts | — | — |
| Clinical Trial Site | Detroit | Michigan | — | — |
| Clinical Trial Site | Rochester | Minnesota | — | — |
| Clinical Trial Site | Joplin | Missouri | 64804 | — |
| Clinical Trial Site | St Louis | Missouri | — | — |
| Clinical Trial Site | Cooperstown | New York | — | — |
| Clinical Trial Site | New York | New York | 10029 | — |
| Clinical Trial Site | New York | New York | 10032 | — |
| Clinical Trial Site | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02510261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02510261 live on ClinicalTrials.gov.